首页> 外文期刊>European Journal of Pharmacology: An International Journal >Improved survival with simendan after experimental myocardial infarction in rats.
【24h】

Improved survival with simendan after experimental myocardial infarction in rats.

机译:实验性心肌梗死后西门丹酮可提高存活率。

获取原文
获取原文并翻译 | 示例
           

摘要

This study compared the effects of simendan, a calcium sensitizer, with those of milrinone and enalapril on survival of rats with healed myocardial infarction. Seven days after ligation-induced myocardial infarction, the rats were randomized to control, milrinone, enalapril, or simendan groups. All compounds were administered via the drinking water for 312 days, at which time there was 80% mortality in the control group--the study's primary endpoint. The infarct sizes were similar across all groups. At endpoint, the mortality rates were: 63% (milrinone), 56% (enalapril) and 53% (simendan); the risk reductions were 25% (P = 0.04 vs. control) and 28% (P = 0.02 vs. control) with enalapril and simendan, respectively. Milrinone had no statistically significant effect on the survival rate. These findings suggest that, like enalapril, simendan improved survival in rats with healed myocardial infarction.
机译:这项研究比较了钙敏化剂西门丹,米力农和依那普利对心肌梗塞病愈后大鼠存活的影响。结扎诱导的心肌梗塞后7天,将大鼠随机分为对照组,米力农,依那普利或西门丹组。所有化合物均通过饮用水给药312天,而对照组的死亡率为80%,这是研究的主要终点。所有组的梗死面积相似。在终点时,死亡率为:63%(米力农),56%(依那普利)和53%(西门丹);与依那普利和西门丹相比,风险降低分别为25%(与对照组相比,P = 0.04)和28%(与对照组相比,P = 0.02)。米力农对生存率无统计学意义。这些发现表明,西咪丹与依那普利一样,可以改善心肌梗死后大鼠的存活率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号